Iterum gains on U.S. patent office clearance for antibiotic combination therapy

Iterum Therapeutics

15/12/2022 15:54

** U.S.-listed shares  ITRM.O  of Dublin-based drug
developer Iterum Therapeutics rise 25.4% to $1.43
    ** Company says U.S. Patent and Trademark Office (USPTO) has
issued a "Notice of Allowance" that covers the use of its oral
antibiotic combination therapy etzadroxil/probenecid 
    ** The combination candidate is being developed to treat
multiple diseases, including uncomplicated urinary tract
infections (UTI), company says
    ** "Notice of Allowance" concludes the primary examination
of the patent application and will result in issuance of U.S.
patent after administrative processes are completed
    ** Addition of the new patent which, when issued, will
afford protection until at least 2039, according to company
    ** ITRM says enrollment in late-stage clinical trial for the
combination therapy in treating UTI is ongoing 
    ** Company expects to provide trial update following interim
analysis at 50% patient enrollment
    ** Including session's gain, stock down ~75% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))